Gene Therapy: Nonclinical Questions Do Not Seem Ideal For The US FDA’s New Type D Meeting

Nonclinical testing questions should be answered in a pre-IND meeting, rather than the new Type D session. A US FDA Center for Biologics Evaluation and Research official also indicated support for alternatives to animal testing when possible.